INT124944

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 2004
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 11.84
Pain Relevance 0.24

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (KIT) extracellular space (KIT) plasma membrane (KIT)
nucleus (KIT) cytoplasm (KIT)
KIT (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 7 75.60 Quite High
Central nervous system 20 72.08 Quite High
abdominal pain 7 68.00 Quite High
Inflammation 12 56.24 Quite High
cva 4 22.16 Low Low
imagery 12 5.00 Very Low Very Low Very Low
depression 7 5.00 Very Low Very Low Very Low
headache 7 5.00 Very Low Very Low Very Low
cytokine 5 5.00 Very Low Very Low Very Low
tolerance 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Lipoma 1 99.60 Very High Very High Very High
Thyroid Neoplasm 4 99.48 Very High Very High Very High
Cancer 367 99.46 Very High Very High Very High
Gastrointestinal Stromal Tumor 203 99.28 Very High Very High Very High
Liposarcoma 13 98.60 Very High Very High Very High
Melanoma 34 97.88 Very High Very High Very High
Disease 202 97.44 Very High Very High Very High
Myeloid Leukemia 34 96.92 Very High Very High Very High
Cutaneous Melanoma 2 96.76 Very High Very High Very High
Skin Cancer 223 96.24 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Imatinib, a tyrosine kinase (TKI) inhibitor, antagonizes the effects of the KIT and PDGFRA proteins and has revolutionized the treatment of advanced and unresectable GISTs [5].
Regulation (effects) of KIT
1) Confidence 0.60 Published 2010 Journal World J Surg Oncol Section Body Doc Link PMC2965163 Disease Relevance 0.69 Pain Relevance 0.07
The discovery that dysregulation in the KIT tyrosine kinase activity underlies the pathogenesis of GIST has led to the development of a novel systemic tyrosine kinase inhibitor, imatinib[5].
Regulation (dysregulation) of KIT associated with gastrointestinal stromal tumor
2) Confidence 0.60 Published 2007 Journal J Med Case Reports Section Body Doc Link PMC2194709 Disease Relevance 1.80 Pain Relevance 0
Further, we will examine differences in levels of burden and well-being between the study group, those who received the GPS kit and their family member, and the control group, those who did not receive the GPS tracking kit and their family members.
Regulation (received) of kit
3) Confidence 0.44 Published 2008 Journal BMC Geriatr Section Body Doc Link PMC2291469 Disease Relevance 0.13 Pain Relevance 0
The tumor cells that reacted to antibodies directed against HepPar1, CAM 5.2, CK19 and scattered cells were immunoreactive for CD117, CD34, and CD56.
Regulation (immunoreactive) of CD117 associated with cancer
4) Confidence 0.39 Published 2005 Journal Mod. Pathol. Section Abstract Doc Link 15696116 Disease Relevance 0.68 Pain Relevance 0.08
With the QIAamp kit, yields were not affected by different storage methods.

454/Roche pyrosequence analysis

Neg (not) Regulation (affected) of kit
5) Confidence 0.30 Published 2010 Journal BMC Microbiol Section Body Doc Link PMC2921404 Disease Relevance 0 Pain Relevance 0
Sequence changes in genes targeted by these miRNAs could contribute to the regulation of Kit involved in PTC pathogenesis [27].
Regulation (regulation) of Kit associated with thyroid neoplasm
6) Confidence 0.29 Published 2007 Journal Mol Cancer Section Body Doc Link PMC2098778 Disease Relevance 0.59 Pain Relevance 0
It specifically targets the c-kit (CD117) proto-oncogene gain of function mutation characterising GISTs, blocking the c-kit kinase, leading to growth cessation and significant durable clinical remissions.
Regulation (targets) of kit
7) Confidence 0.27 Published 2004 Journal BMC Cancer Section Body Doc Link PMC524360 Disease Relevance 0.73 Pain Relevance 0.04
It specifically targets the c-kit (CD117) proto-oncogene gain of function mutation characterising GISTs, blocking the c-kit kinase, leading to growth cessation and significant durable clinical remissions.
Regulation (targets) of CD117
8) Confidence 0.27 Published 2004 Journal BMC Cancer Section Body Doc Link PMC524360 Disease Relevance 0.74 Pain Relevance 0.04
A wide range of newer and more potent small molecule TKI that target KIT and/or PDGRA are in development.
Regulation (target) of KIT
9) Confidence 0.23 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2819895 Disease Relevance 1.02 Pain Relevance 0
On immunohistochemistry, lipoma-like cells stained positive for S100, vimentin and calretinin but not for p53, p21 WaF1, and c-kit, indicating a well-differentiated liposarcoma.
Neg (not) Regulation (positive) of c-kit associated with liposarcoma and lipoma
10) Confidence 0.11 Published 2007 Journal World J Surg Oncol Section Body Doc Link PMC1866233 Disease Relevance 0.67 Pain Relevance 0
Several agents targeting these molecular aberrations, including drugs targeting the c-KIT and BRAFV600E mutations, are currently being evaluated in clinical trials.
Regulation (targeting) of KIT
11) Confidence 0.10 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004577 Disease Relevance 0.81 Pain Relevance 0
In a retrospective analysis of biopsy specimens from 189 melanoma lesions, mutations of c-KIT exons 11, 13, and 17 were observed in 1.7% of cutaneous melanomas, 23% of acral melanomas, and 15.6% of mucosal melanomas.132 Several small-molecule tyrosine kinase inhibitors that are approved by the FDA for other indications target c-KIT including sunitinib, imatinib, nilotinib, and dasatinib.
Regulation (target) of KIT associated with melanoma, cutaneous melanoma and skin cancer
12) Confidence 0.09 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004577 Disease Relevance 1.14 Pain Relevance 0
Sunitinib is an orally-active small molecule tyrosine kinase inhibitor that acts on multiple targets including VEGFR, PDGFR, c-kit and Flt-3.[46] In a phase II, open-label, multicenter study, sunitinib was evaluated as monotherapy in patients with MBC. 64 patients previously treated with an anthracycline and a taxane received sunitinib 50 mg daily in six week cycles, and results showed that 7 patients achieved a partial response with a median duration of 19 weeks giving an ORR of 11%. 3 patients achieved stable disease for greater than 6 months.
Regulation (targets) of c-kit associated with disease and advanced or metastatic breast cancer
13) Confidence 0.07 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 1.30 Pain Relevance 0.03
Importantly, lessons learned from patients with CML have been applied successfully for the treatment of patients with other disorders where IM has since been found to be active by virtue of its ability to target other kinases, such as c-kit in patients with gastrointestinal stromal tumors.
Regulation (target) of c-kit associated with myeloid leukemia and gastrointestinal stromal tumor
14) Confidence 0.07 Published 2010 Journal Biologics : Targets & Therapy Section Abstract Doc Link PMC3010822 Disease Relevance 0.63 Pain Relevance 0
TFAP2A plays crucial role in tumor growth and progression by regulation of E-cadherin, MMP-2, c-kit, p21WAF-1, HER-2, BCL-2, insulin like growth factor receptor-1 and Smad signaling [25].
Regulation (regulation) of c-kit associated with cancer
15) Confidence 0.04 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2958829 Disease Relevance 0.92 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox